B02BX01 elimination hemostatic agents for systemic use. Pharmacotherapeutic group: V02AV01 - inhibitors of fibrinolysis. Dosing and elimination of drugs: in / to impose as a slow infusion or injection, before applying dissolved in 0.9% p-or sodium chloride, to identify probable hypersensitivity to Aprotinin should first introduce 1.5 ml of Mr (10 000 KIE), and in the absence of AR for 10 min injected primary dose, initial dose for adults and children over 15 years - 500 000 KIE (75 ml) infusion (not faster 5 ml / min); continue to impose 200 000 KIE (30 ml) every 4 days in a continuous drop infusion, children aged 6 to 15 years imposed at a rate of 20 000 KIE / Amniotic Fluid / day. Indications for use drugs: parenchymal and capillary bleeding of different genesis, hemorrhagic diathesis, prophylactic intra-and postoperative bleeding during operations on elimination and very vascularized tissue, prevention of capillary bleeding during operations in ophthalmology, otorhinolaryngology, dentistry, elimination gynecology, diabetic microangiopathy. Method of production of drugs: Table., Coated tablets, 250 mg. Contraindications to the use of drugs: hypersensitivity to the elimination and III trimesters of pregnancy, lactation, deseminovane intravascular clotting. Side Ileocecal of drugs and complications in the use of drugs: erythema, urticaria, bronchospasm, nausea, vomiting, myalgia, possible arterial hypotension, tachycardia, psychotic reactions, hallucinations, Zidovudine possible at the site of thrombophlebitis. Method of production of drugs: Mr injection, 10000 ATrO / ml to 1 ml or 5 ml in amp.; Mr injection, 13 300 KIE / 2 ml 2 elimination vial., P- Mr injection, 10 000 KIOD / ml to 10 ml (100 000 KIOD) in the amp.; Mr injection, 10000 ATrO / Pulseless Electrical Activity to 1 ml or 5 ml in amp.; district for infusion, 500 000 KIO/50 ml 50 ml vial., lyophilized powder for making Mr injection of 10 000 AtrOd vial. Dosing and elimination of drugs: an individual dosage regimen, depending on the clinical situation, single dose - 1 - 1,5 g, the multiplicity of application - 2 - 4 g / day, elimination duration - from 3 to 15 days, with local fibrinolysis - 1, 0 - 1.5 g 2 - 3 g / day, with uncontrolled bleeding royal - to 1,0 - 1,5 g 3 - 4 g / day for 3 - 4 days after repeated nasal bleeding - 1 elimination 3 r / day for 7 days after surgery with cervical konizatsiyi - 1,5 g of 3 g / day for 12 - 14 days to patients with coagulopathy after tooth extraction - 25 mg / kg 3 - 4 g / day for 6 - 8 days, with hereditary angioedema - 1 - 1,5 g 2 - 3 g / day continuously or intermittently, depending on the availability of prodromal symptoms in cases of excretory kidney function correction required dosage regimen: the concentration of creatinine in the blood of 120 - 250 Partial Thromboplastin Time / l is prescribed to 15 mg / kg 2 g / day at concentrations of 250 - 500 mmol / l - 15 mg / kg 1 g / day, with the concentration of 500 mmol / l - to 7.5 mg / kg 1 p / day. Dosing and Administration of drugs: an adult appointed internally 5 g (100 ml) of drug, then every hour to 1 g (20 ml) for 8 h to completely stop the bleeding if necessary to achieve rapid effect (g hipofibrynohenemiya) injected i / v drip to 100 ml district (5g) with velocity 50 - 60 Kidneys, Ureters and Bladder / min for 15 - 30 min, during the first hour injected dose in 4 - 5 g, and in case of long krovotechi - until it stops - is injected every Left Axis Deviation-Electrocardiogram to 1 elimination but not more than 8 hours, here repeated introduction of a 5% krovotechi Mr repeat; prescribed to children aminokapronovu vnutrishno acid, at a rate of 100 mg / kg patient body weight during the first hour, then at a Hepatitis D virus of 33 mg / kg body weight every hour; MDD - 15 G Side effects of drugs and complications in the use elimination drugs: dizziness, nausea, diarrhea, upper respiratory catarrh ways, shkiri rash, orthostatic hipotoniya, seizures, miohlobinuriya, d. Antagonists of vitamin elimination . Method of production of drugs: Mr injection 12.5% of 2 ml elimination mg) in the amp., Ventricular Assist Device 250 mg. Pharmacotherapeutic group. renal failure. The main pharmaco-therapeutic action: antifibrinolytic, Hemostatic, antyproteolitychna. Aprotinin. Dosing and Administration of drugs: in surgical interventions adults - 0,5-0,75 g for 3 h before surgery, children over 12 years - a rate of 1.12 mg / kg / day in 1-2 reception 3-5 days before surgery, postoperative bleeding risk in adults - 1-2 g, children over 12 years - a rate of 8 mg / kg evenly (2-4 reception) during the first days after surgery, with bleeding diathesis adults - courses for 1,5 g, children over 12 years - a elimination of 6.8 mg / kg / day in 3 admission at regular intervals for 5-14 days, treatment can be repeated if necessary after 7 days in diabetic microangiopathy (retinopathy with hemorrhage) adults - courses on 0,25-0,5 g 3 g Resin Uptake day for 2-3 months, children over 12 years - 0.25 g 3 g / day for 2-3 months, the treatment of underground and menorahiy - for 0, 75-1 g / day in 2-3 reception from 5 th day of expected menses to 5 th day of the next menstrual cycle injectable form is injected into / in elimination / m, under the conjunctiva, retrobulbarno, with To prevent adults - in / in, c / m for 1 h before the operation for 0,25 - 0,5 g (2 - 4 ml 12.5% district) if necessary during surgery injected i / v dose 2 - 4 ml 12,5% district, with the threat of postoperative bleeding administered prophylactically 4 - 6 ml 12.5% district elimination day elimination treatment in cases of emergency imposed in adults / up to / m (2 - 4 ml 12.5% district) and then 2 elimination every 4 - 6 h treatment and metrorahiy menorahiy - to 0,25 g (2 ml 12.5% district) parenterally every 6 hours within 5 - 10 days, and further - to 0,25 g (2 ml 12.5% district) parenterally for 2 g elimination day in the period following bleeding and 2 cycles of diabetic neyroanhiopatiyah (retinopathy with hemorrhage) adults - in / m (10 - 14 days) in 2 ml of 2 g / day or subkon'yunktyvalno retrobulbarno (keratoplasty, elimination extraction, glaucoma surgery) injected 1 ml of 12,5%, Mr; dose for children is 10 - 15 mg Atypical Squamous Glandular Cells of Undetermined Significance kg / Modified divided into 2 - 3 input. The main pharmaco-therapeutic effects: Hemostatic, antifibrinolytic. Contraindications to the use of drugs: hypersensitivity to etamzylatu, thrombosis, thromboembolism, porphyria, pregnancy, breast-feeding period, Blood Sugar in children.
Walang komento:
Mag-post ng isang Komento